"align=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> At Week 0, subjects received 160 mg of TALTZ, followed by 80 mg every 2 weeks for 12 weeks.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Endpoints</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg Q2W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">n (%)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of subjects randomized</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=75</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=74</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">       sPGA of Genitalia “0” (clear) or “1” (minimal)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">55 (73%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6 (8%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">       sPGA “0” (clear) or “1” (minimal)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">55 (73%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2 (3%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of subjects with baseline GPSS</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span><span class=\\\"Bold\\\">Itch NRS Score ≥4</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=56</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=51</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">       GPSS Genital Itch (≥4 point improvement)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31 (55%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3 (6%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of subjects with baseline GenPs-SFQ</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span><span class=\\\"Bold\\\">Item 2 Score ≥2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=37</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=42</span></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">       GenPs-SFQ Item 2 score “0” (never) or “1” (rarely)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">29 (78%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9 (21%)</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s70\\\"></a><a name=\\\"section-11.2\\\"></a><p></p><h2>14.2 Pediatric Plaque Psoriasis</h2><p class=\\\"First\\\">A randomized, double-blind, multicenter, placebo-controlled trial (IXORA-Peds, NCT03073200) enrolled 171 pediatric subjects 6 to less than 18 years of age, with moderate-to-severe plaque psoriasis (as defined by a sPGA score ≥3, involving ≥10% of the body surface area, and a PASI score ≥12) who were candidates for phototherapy or systemic therapy or were inadequately controlled on topical therapy.</p><p>Subjects were randomized to placebo or TALTZ with dosing stratified by weight.</p><ul class=\\\"Disc\\\"><li>&lt;25 kg: 40 mg at Week 0 followed by 20 mg Q4W</li><li>25 kg to 50 kg: 80 mg at Week 0 followed by 40 mg Q4W</li><li>&gt;50 kg: 160 mg at Week 0 followed by 80 mg Q4W</li></ul><p>Response to treatment was assessed at 12 weeks of therapy and was defined by the proportion of subjects who achieved an sPGA score of “0” (clear) or “1” (almost clear) with at least a 2-point improvement from baseline and the proportion of subjects that achieved a reduction in PASI score of at least 75% (PASI 75) from baseline.</p><p>Other evaluated outcomes included the proportion of subjects who achieved PASI 90, PASI 100, sPGA of “0” and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.</p><p>Subjects had a median baseline PASI score of 17 (range 12-49). Baseline sPGA score was severe or very severe in 49%. Of all subjects, 22% had received prior phototherapy and 32% had received prior conventional systemic therapy for the treatment of psoriasis.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s70a\\\"></a><a name=\\\"section-11.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Response</span></p><p>The efficacy results of IXORA-Peds are presented in Table 5.</p><a name=\\\"t5\\\"></a><table width=\\\"100%\\\"><caption><span>Table 5: Efficacy Results in Pediatric Subjects with Plaque Psoriasis in IXORA-Peds, NRI<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"36.667%\\\"/><col align=\\\"left\\\" width=\\\"31.667%\\\"/><col align=\\\"left\\\" width=\\\"31.667%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: N = Number of subjects in the intent-to-treat population; NRI = Non-Responder Imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> At Week 0, subjects received 160 mg, 80 mg, or 40 mg of TALTZ, followed by 80 mg, 40 mg, or 20 mg every 4 weeks, depending on weight category, for 12 weeks.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Co-primary endpoints.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Itch NRS (≥4 improvement) in subjects with baseline Itch NRS ≥4. The number of ITT subjects with baseline Itch NRS Score ≥4 are as follows: TALTZ, n = 83; PBO, n = 40.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><span class=\\\"Bold\\\"><br/>(N=115)<br/>n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo<br/>(N=56)<br/>n (%)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Week 12</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">   sPGA “0” (clear) or “1” (minimal)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">93 (81%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6 (11%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">   sPGA “0” (clear)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">60 (52%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 (2%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">   <span class=\\\"Bold\\\">PASI 75</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">102 (89%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14 (25%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">   <span class=\\\"Bold\\\">PASI 90</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">90 (78%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3 (5%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">   <span class=\\\"Bold\\\">PASI 100</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">57 (50%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 (2%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">   Itch NRS (≥4 point improvement)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">d</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">59 (71%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8 (20%)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Week 4</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">   sPGA “0” (clear) or “1” (minimal)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">55 (48%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4 (7%)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">   <span class=\\\"Bold\\\">PASI 75</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">62 (54%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5 (9%)</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s73\\\"></a><a name=\\\"section-11.3\\\"></a><p></p><h2>14.3 Psoriatic Arthritis</h2><p class=\\\"First\\\">The safety and efficacy of TALTZ were assessed in 679 patients, in 2 randomized, double-blind, placebo-controlled studies (PsA1 and PsA2) in adult patients, age 18 years and older with active psoriatic arthritis (at least 3 swollen and at least 3 tender joints) despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease modifying anti-rheumatic drug (DMARD) therapy. Patients in these studies had a diagnosis of PsA for at least 6 months across both studies. At baseline, 60% and 23% of the patients had enthesitis and dactylitis, respectively. In PsA2, all patients discontinued previous treatment with anti-TNFα agents due to either inadequate response or intolerance. In addition, approximately 47% of patients from both studies had concomitant methotrexate (MTX) use.</p><p>PsA1 Study (NCT 01695239) evaluated 417 biologic-naive patients, who were treated with either TALTZ 160 mg at Week 0 followed by 80 mg every 2 weeks (Q2W) or 4 weeks (Q4W), adalimumab 40 mg every 2 weeks, or placebo. PsA2 Study (NCT 02349295) evaluated 363 anti-TNFα experienced patients, who were treated with TALTZ 160 mg at Week 0 followed by 80 mg every 2 or 4 weeks, or placebo. Patients receiving placebo were re-randomized to receive TALTZ (80 mg every 2 or 4 weeks) at Week 16 or Week 24 based on responder status. The primary endpoint was the percentage of patients achieving an ACR20 response at Week 24.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s74\\\"></a><a name=\\\"section-11.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Response</span></p><p>In both studies, patients treated with TALTZ 80 mg Q4W demonstrated a greater clinical response including ACR20, ACR50, and ACR70 compared to placebo at Week 24 (<a href=\\\"#t6\\\">Table 6</a>). In PsA2, responses were seen regardless of prior anti-TNFα exposure.</p><a name=\\\"t6\\\"></a><table width=\\\"100%\\\"><caption><span>Table 6: Responses<span class=\\\"Sup\\\">a</span> at Week 12 and 24; NRI<span class=\\\"Sup\\\">b</span></span></caption><col align=\\\"left\\\" width=\\\"17.329%\\\"/><col align=\\\"left\\\" width=\\\"13.786%\\\"/><col align=\\\"left\\\" width=\\\"10.143%\\\"/><col align=\\\"left\\\" width=\\\"17.329%\\\"/><col align=\\\"left\\\" width=\\\"13.857%\\\"/><col align=\\\"left\\\" width=\\\"10.071%\\\"/><col align=\\\"left\\\" width=\\\"17.486%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Patients who met escape criteria (less than 20% improvement in tender and swollen joint counts) at Week 16 or had missing data at Week 24 were considered non-responders at Week 24.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> At Week 0, patients received 160 mg of TALTZ.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PsA1 – anti-TNFα naive</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PsA2 – anti-TNFα – experienced</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><br/><span class=\\\"Bold\\\">80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span><br/><span class=\\\"Bold\\\">Q4W</span><br/><span class=\\\"Bold\\\">(N=107)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo (N=106)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Difference from placebo (95% CI)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><br/><span class=\\\"Bold\\\">80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span><br/><span class=\\\"Bold\\\">Q4W</span><br/><span class=\\\"Bold\\\">(N=122)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo (N=118)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Difference from placebo (95% CI)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ACR20 response</span></td></tr><tr><td align=\\\"right\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12 (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">57</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">26 (13, 39)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">50</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">22</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">28 (16, 40)</td></tr><tr><td align=\\\"right\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24 (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">58</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">28 (15, 41)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">53</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">34 (22, 45)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ACR50 response</span></td></tr><tr><td align=\\\"right\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12 (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">34</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">29 (19, 39)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">28 (19, 37)</td></tr><tr><td align=\\\"right\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24 (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">40</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">25 (14, 37)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">35</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30 (21, 40)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ACR70 response</span></td></tr><tr><td align=\\\"right\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12 (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15 (8, 22)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13 (6, 20)</td></tr><tr class=\\\"Last\\\"><td align=\\\"right\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24 (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">18 (9, 27)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">22</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">22 (15, 30)</td></tr></tbody></table><p>The percentage of patients achieving ACR20 response by visit is shown in <a href=\\\"#fig1\\\">Figure 1</a>.</p><p class=\\\"MultiMediaCazption\\\"><a name=\\\"fig1\\\"></a><span class=\\\"Bold\\\">Figure 1: Percent of Patients Achieving ACR20 Response</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span><span class=\\\"Bold\\\">in PsA1 Through Week 24</span></p><div class=\\\"Figure\\\"><a name=\\\"f01\\\"></a><img alt=\\\"Figure 1\\n\\\" src=\\\"taltz-uspi-1-v1.jpg\\\"/></div><p><span class=\\\"Sup\\\">a</span> Patients who met escape criteria (less than 20% improvement in tender and swollen joint counts) at Week 16 or had missing data at Week 24 were considered non-responders at Week 24.</p><p>The improvements in the components of the ACR response criteria are shown in <a href=\\\"#t7\\\">Table 7</a>.</p><a name=\\\"t7\\\"></a><table width=\\\"100%\\\"><caption><span>Table 7: Efficacy results in ACR Components at Week 12 and 16</span></caption><col align=\\\"left\\\" width=\\\"34.160%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> At Week 0, subjects received 160 mg of TALTZ.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the patient's ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PsA1</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PsA2</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span><br/><span class=\\\"Bold\\\">Q4W (N=107)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=106)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span><br/><span class=\\\"Bold\\\">Q4W (N=122)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=118)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">No. of Swollen Joints</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">10.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">10.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-6.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-6.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">No. of Tender Joints</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">22.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-4.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Patient's Assessment of Pain</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">60.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">58.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">63.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">63.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-26.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-29.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-26.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-30.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-12.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Patient Global Assessment</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">62.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">61.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">66.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">64.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-29.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-34.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-30.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-13.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-35.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-15.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Physician Global Assessment</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">57.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">55.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">60.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">58.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-34.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-16.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-34.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-15.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-35.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-16.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-32.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Disability Index (HAQ-DI)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CRP (mg/L)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">17.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-8.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-4.3</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Mean Change at Week 16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.9</td></tr></tbody></table><p>Treatment with TALTZ resulted in improvement in dactylitis and enthesitis in patients with pre-existing dactylitis or enthesitis.</p><p>Treatment with TALTZ 80 mg Q4W resulted in an improvement in psoriatic skin lesions in patients with PsA.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s75\\\"></a><a name=\\\"section-11.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Radiographic Response</span></p><p>Radiographic changes were assessed in PsA1. Inhibition of progression of structural damage was assessed radiographically and expressed as the change in modified total Sharp score (mTSS) at Week 16, compared to baseline. The total Sharp score was modified for psoriatic arthritis by addition of hand distal interphalangeal (DIP) joints.</p><p>TALTZ 80 mg Q4W inhibited the progression of structural joint damage (mTSS) compared to placebo at Week 16. The adjusted mean change from baseline in the mTSS was 0.13 for TALTZ 80 mg Q4W and 0.36 for placebo (difference in means TALTZ minus placebo: -0.23, 95% CI: (-0.42, -0.04)).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s76\\\"></a><a name=\\\"section-11.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Physical Function</span></p><p>TALTZ treated patients showed improvement in physical function compared to patients treated with placebo as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 and 24. In both studies, the proportion of HAQ-DI responders (≥0.35 improvement in HAQ-DI score) was greater in the TALTZ 80 mg Q4W groups compared to placebo at week 12 and 24.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s77\\\"></a><a name=\\\"section-11.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Other Health-Related Outcomes</span></p><p>General health status was assessed by the Short Form health survey (SF-36). At Week 12 in PsA1 and PsA2, patients treated with TALTZ showed greater improvement from baseline in the SF-36 physical component summary (PCS) score compared to patients treated with placebo but this improvement was not consistent in both studies for the SF-36 mental component summary (MCS) score. At Week 12, there was consistent evidence of effect in the physical-functioning, role-physical, bodily-pain, and general health domains but not in the social-functioning, role-emotional, vitality, and mental health domains.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s78\\\"></a><a name=\\\"section-11.4\\\"></a><p></p><h2>14.4 Ankylosing Spondylitis</h2><p class=\\\"First\\\">The safety and efficacy of TALTZ were assessed in 567 patients, in 2 randomized, double-blind, placebo-controlled studies (AS1 and AS2) in adult patients, age 18 years and older with active ankylosing spondylitis. Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid, or disease modifying anti-rheumatic drug (DMARD) therapy. At baseline, patients had symptoms of AS for an average of 17 years across both studies. At baseline, approximately 32% of the patients were on a concomitant cDMARD. In AS2, all patients discontinued previous treatment with 1 or 2 TNF inhibitors due to either inadequate response or intolerance.</p><p>AS1 Study (NCT 02696785) evaluated 341 biologic-naive patients, who were treated with either TALTZ 80 mg or 160 mg at Week 0 followed by 80 mg every 2 weeks (Q2W) or 4 weeks (Q4W), adalimumab 40 mg every 2 weeks, or with placebo. Patients receiving placebo were re-randomized at Week 16 to receive TALTZ (160 mg starting dose, followed by 80 mg Q2W or Q4W). Patients receiving adalimumab were re-randomized at Week 16 to receive TALTZ (80 mg Q2W or Q4W). AS2 Study (NCT 02696798) evaluated 316 TNF-inhibitor experienced patients (90% were inadequate responders and 10% were intolerant to TNF inhibitors). All patients were treated with TALTZ 80 or 160 mg at Week 0 followed by 80 mg Q2W or Q4W, or with placebo. Patients receiving placebo were re-randomized at Week 16 to receive TALTZ (160 mg initial dose, followed by 80 mg Q2W or Q4W). The primary endpoint in both studies was the percentage of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 16.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s79\\\"></a><a name=\\\"section-11.4.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Response</span></p><p>In both studies, patients treated with TALTZ 80 mg Q4W demonstrated greater improvements in ASAS40 and ASAS20 responses compared to placebo at Week 16 (<a href=\\\"#t8\\\">Table 8</a>). Responses were seen regardless of concomitant therapies. In AS2, responses were seen regardless of prior TNF-inhibitor exposure.</p><a name=\\\"t8\\\"></a><table width=\\\"100%\\\"><caption><span>Table 8: ASAS20 and ASAS40 Responses at Week 16, NRI<span class=\\\"Sup\\\">a,b</span></span></caption><col align=\\\"left\\\" width=\\\"17.431%\\\"/><col align=\\\"left\\\" width=\\\"13.659%\\\"/><col align=\\\"left\\\" width=\\\"10.287%\\\"/><col align=\\\"left\\\" width=\\\"17.260%\\\"/><col align=\\\"left\\\" width=\\\"13.745%\\\"/><col align=\\\"left\\\" width=\\\"10.201%\\\"/><col align=\\\"left\\\" width=\\\"17.417%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-responder Imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Patients with missing data were counted as non-responders.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> At Week 0, patients received 80 mg or 160 mg of TALTZ.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> An ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. An ASAS40 response is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units in ≥3 of 4 domains without any worsening in the remaining domain.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">e</span> Primary endpoint.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">AS1 – biologic-naive</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">AS2 – TNF-inhibitor experienced</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><br/><span class=\\\"Bold\\\">80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span><br/><span class=\\\"Bold\\\">(N=81)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo (N=87)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Difference from placebo (95% CI)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><br/><span class=\\\"Bold\\\">80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span><br/><span class=\\\"Bold\\\">(N=114)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo (N=104)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Difference from placebo (95% CI)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">ASAS20 response<span class=\\\"Sup\\\">d</span>, %</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">64</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">40</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">24 (9, 39)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">48</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">18 (6, 31)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">ASAS40 response<span class=\\\"Sup\\\">d,e</span>, % </td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">48</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">18</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30 (16, 43)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">25</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13 (3, 23)</td></tr></tbody></table><p>The percent of patients achieving ASAS40 response by visit in AS1 is shown in <a href=\\\"#fig2\\\">Figure 2</a>.</p><p class=\\\"MultiMediaCazption\\\"><a name=\\\"fig2\\\"></a><span class=\\\"Bold\\\">Figure 2: ASAS40 Response through Week 16, NRI</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></p><div class=\\\"Figure\\\"><a name=\\\"f02\\\"></a><img alt=\\\"Figure 2\\n\\\" src=\\\"taltz-uspi-2-v1.jpg\\\"/></div><p><span class=\\\"Sup\\\">a</span> Patients with missing data were counted as non-responders.</p><p>The improvement in the main components of the ASAS40 response criteria and other measures of disease activity are shown in <a href=\\\"#t9\\\">Table 9</a>.</p><a name=\\\"t9\\\"></a><table width=\\\"100%\\\"><caption><span>Table 9: ASAS Components and Other Measures of Disease Activity at Week 16<span class=\\\"Sup\\\">a,b</span></span></caption><col align=\\\"left\\\" width=\\\"34.160%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><col align=\\\"left\\\" width=\\\"16.460%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; hsCRP = High sensitivity C-reactive protein.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Mean changes are least-squares mean changes from baseline at Week 16.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> At Week 0, patients received 80 or 160 mg of TALTZ.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Inflammation is the mean of patient-reported stiffness self-assessments (questions 5 and 6) in BASDAI.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">AS1 – biologic-naive</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">AS2 – TNF-inhibitor experienced</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span><span class=\\\"Bold\\\">(N=81)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=87)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span><span class=\\\"Bold\\\">(N=114)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=104)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ASAS Components</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     Patient Global Assessment (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     Total Spinal Pain (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     BASFI (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     Inflammation (0-10)<span class=\\\"Sup\\\">d</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Other Measures of Disease Activity</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     BASDAI Score</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     BASMI</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\">     hsCRP (mg/L)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16.0</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9.7</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80\\\"></a><a name=\\\"section-11.4.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Health-Related Outcomes</span></p><p>General health status and quality of life was assessed by the Short Form health survey (SF-36). At Week 16, in AS1 and AS2, compared to placebo, patients treated with TALTZ showed greater improvement from baseline in the SF-36 physical component summary (PCS) score and the physical functioning, role physical, bodily pain, vitality, and general health domains, with no consistent improvements in the mental component summary (MCS), social functioning, role emotional, and mental health domains.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80a\\\"></a><a name=\\\"section-11.5\\\"></a><p></p><h2>14.5 Non-radiographic Axial Spondyloarthritis</h2><p class=\\\"First\\\">The efficacy and safety of TALTZ were assessed in a randomized, double-blind, 52-week placebo-controlled study (nr-axSpA1) (NCT 02757352) in patients ≥18 years of age with active axial spondyloarthritis for at least 3 months. Patients must have had objective signs of inflammation indicated by elevated C-reactive protein (CRP) (defined as greater than 5 mg/L), and/or sacroiliitis on magnetic resonance imaging (MRI), and no definitive radiographic evidence of structural damage on sacroiliac joints. Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4, and spinal pain ≥4 on a 0 to 10 Numerical Rating Scale (NRS). Patients must have been intolerant to or had an inadequate response to at least two NSAIDs. Patients were treated with either placebo or TALTZ 80 mg or 160 mg at Week 0, followed by either 80 mg every 2 weeks (Q2W) or 80 mg every 4 weeks (Q4W). Initiation and/or dose adjustment of concomitant medications (NSAIDs, cDMARDs, corticosteroids, analgesics) were permitted starting at Week 16. Patients were allowed to transition to use of open-label TALTZ 80 mg Q2W starting at Week 16 up to Week 44 at the discretion of the investigator.</p><p>At baseline, patients had symptoms of nr-axSpA for an average of 11 years. Approximately 39% of the patients were on a concomitant cDMARD.</p><p>The primary endpoint was the percentage of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 52. The ASAS40 response was also evaluated at Week 16 as a major secondary endpoint.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80b\\\"></a><a name=\\\"section-11.5.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Response</span></p><p>At both Weeks 16 and 52, a greater proportion of patients treated with TALTZ 80 mg Q4W had ASAS40 response compared to patients treated with placebo (<a href=\\\"#t10\\\">Table 10</a>). The components of ASAS response criteria and CRP are shown in <a href=\\\"#t11\\\">Table 11</a>.</p><a name=\\\"t10\\\"></a><table width=\\\"100%\\\"><caption><span>Table 10: ASAS40 Responses at Week 16 and Week 52, NRI<span class=\\\"Sup\\\">a,b</span></span></caption><col align=\\\"left\\\" width=\\\"17.431%\\\"/><col align=\\\"left\\\" width=\\\"13.659%\\\"/><col align=\\\"left\\\" width=\\\"10.287%\\\"/><col align=\\\"left\\\" width=\\\"17.260%\\\"/><col align=\\\"left\\\" width=\\\"13.745%\\\"/><col align=\\\"left\\\" width=\\\"10.201%\\\"/><col align=\\\"left\\\" width=\\\"17.417%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-responder Imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Patients who initiated open-label TALTZ 80 mg Q2W, or discontinued initially randomized treatment and remained in the study, or were missing Week 16 or Week 52 data were counted as non-responders.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Starting at Week 16 and up to Week 44, patients who were determined as inadequate responders by investigators were given the option to make changes in their background therapy and/or transition to open label TALTZ 80 mg Q2W.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> At Week 0, patients received 80 mg or 160 mg of TALTZ.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">e</span> An ASAS40 response is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units in ≥3 of 4 domains without any worsening in the remaining domain.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Week 16</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Week 52</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><br/><span class=\\\"Bold\\\">80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c,d</span></span><br/><span class=\\\"Bold\\\">(N=96)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo (N=105)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Difference from placebo (95% CI)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ</span><br/><span class=\\\"Bold\\\">80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c,d</span></span><br/><span class=\\\"Bold\\\">(N=96)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo (N=105)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Difference from placebo (95% CI)</span></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ASAS40 response</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">e</span></span><span class=\\\"Bold\\\">, %</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">35.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16.4 (4.2, 28.5)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16.9 (5.6, 28.1)</td></tr></tbody></table><p>The improvement in the main components of the ASAS40 response criteria and other measures of disease activity at Week 16 are shown in <a href=\\\"#t11\\\">Table 11</a>.</p><a name=\\\"t11\\\"></a><table width=\\\"100%\\\"><caption><span>Table 11: ASAS Components and Other Measures of Disease Activity at Week 16<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"38.200%\\\"/><col align=\\\"left\\\" width=\\\"30.900%\\\"/><col align=\\\"left\\\" width=\\\"30.900%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; hsCRP = High sensitivity C-reactive protein; NRI = Non-responder Imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> At Week 0, patients received 80 or 160 mg of TALTZ.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Mean changes are least-squares mean changes from baseline at Week 16 using a mixed model for repeated measures adjusting for treatment group, screening MRI/CRP classification, visit, continuous baseline, interaction of visit with treatment, interaction of continuous baseline with visit.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Inflammation is the mean of patient-reported stiffness self-assessments (questions 5 and 6) in BASDAI questionnaire.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><br/><span class=\\\"Bold\\\">Q4W</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><span class=\\\"Bold\\\">(N=96)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=105)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ASAS Components</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     Patient Global Assessment (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     Total Spinal Pain (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     BASFI (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     Inflammation (0-10)<span class=\\\"Sup\\\">d</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Other Measures of Disease Activity</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     BASDAI Score (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     BASMI (0-10)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"top\\\">     hsCRP (mg/L)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14.3</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">           Mean Change from Baseline<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-8.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.0</td></tr></tbody></table><p>The percent of patients achieving ASAS40 responses by visit is shown in <a href=\\\"#fig3\\\">Figure 3</a>.<br/><br/></p><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig3\\\"></a><span class=\\\"Bold\\\">Figure 3: ASAS40 Responses through Week 16, NRI</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></p><div class=\\\"Figure\\\"><a name=\\\"f03a\\\"></a><img alt=\\\"Figure 3\\n\\\" src=\\\"taltz-uspi-3-v1.jpg\\\"/></div><p><span class=\\\"Sup\\\">a</span> Patients with missing data were counted as non-responders.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80c\\\"></a><a name=\\\"section-11.5.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Health-Related Outcomes</span></p><p>General health status and quality of life was assessed by the Short Form health survey (SF-36). At Week 16, compared to placebo, nr-axSpA patients treated with TALTZ 80 mg Q4W showed greater improvement from baseline in the SF-36 physical component summary (PCS) score and physical functioning, bodily pain, vitality, and social functioning domains, with no consistent improvements in the mental component summary (MCS), role physical, general health, role emotional, and mental health domains.</p></div></div></section>\",\n            \"howSupplied\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34069-5\\\"><a name=\\\"s82\\\"></a><a name=\\\"section-12.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">How Supplied</span></p><p>TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution available in:                </p><ul class=\\\"Disc\\\"><li>a single-dose prefilled autoinjector or a single-dose prefilled syringe to deliver 80 mg ixekizumab.</li><li>a single-dose prefilled syringe to deliver 40 mg ixekizumab.</li><li>a single-dose prefilled syringe to deliver 20 mg ixekizumab.</li></ul><p>TALTZ is supplied as:</p><table width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"33.333%\\\"/><col align=\\\"left\\\" width=\\\"33.333%\\\"/><col align=\\\"left\\\" width=\\\"33.333%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Pack Size</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">NDC Code</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Autoinjector</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"center\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Carton of 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1445-11</td></tr><tr><td align=\\\"center\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">     80 mg single-dose</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Carton of 2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1445-27</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Carton of 3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1445-09</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Prefilled syringe</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><"